Further identification of CTX-M-2 extended-spectrum beta-lactamase in Pseudomonas aeruginosa.
Picão
Renata Cristina
RC
Poirel
Laurent
L
Gales
Ana C
AC
Nordmann
Patrice
P
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D001938:Brazil; D002443:Ceftriaxone / Q000494:pharmacology / Q000627:therapeutic use; D002981:Clindamycin / Q000494:pharmacology / Q000627:therapeutic use; D024901:Drug Resistance, Multiple, Bacterial; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000302:isolation & purification; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000096:biosynthesis* / Q000145:classification* / Q000235:genetics
D000900:Anti-Bacterial Agents; D002981:Clindamycin; D002443:Ceftriaxone; C071167:beta-lactamase CTX-2; D001618:beta-Lactamases